Analysis of KIT (CD117) expression in gallbladder carcinomas by tissue microarray

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Cord LangnerP Kornprat

Abstract

KIT (CD117) is a transmembrane tyrosinase-kinase receptor which has been related to cell proliferation, differentiation, adhesion and control of apoptosis. If present, KIT may provide a suitable target for tumour therapy. In this study, we report the presence of KIT in primary and metastatic gallbladder carcinomas. Formalin-fixed and paraffin-embedded specimens of 57 primary gallbladder carcinomas and 18 corresponding metastases were stained using a tissue microarray technique and two different antibodies. Only three tumours stained for KIT. With a polyclonal antibody only one well differentiated papillary adenocarcinoma was immunoreactive. With a monoclonal antibody two additional poorly differentiated tubular adenocarcinoma showed weak and focal immunostaining. KIT immunoreactivity is infrequent in gallbladder carcinoma. Thus, routine screening of tumour tissues for KIT by immunohistochemistry appears to be cost-ineffective and cannot be recommended. Moreover, the lack of substantial KIT immunoreactivity in both primary and metastatic gallbladder carcinoma tissues does not provide a rationale to investigate imatinib mesylate therapy in clinical trials including patients with advanced disease.

References

Nov 1, 1995·The Journal of Pathology·M A IzquierdoG Giaccone
Jul 14, 1998·Nature Medicine·J KononenO P Kallioniemi
Dec 29, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K K KuoM Tanaka
Oct 7, 2000·The American Journal of Surgical Pathology·C Ortiz-HidalgoJ Albores-Saavedra
Mar 27, 2002·The American Journal of Surgical Pathology·Brandon E SmitheyD Ashley Hill
Jul 3, 2002·Human Pathology·Christopher D M FletcherSharon W Weiss
Aug 7, 2002·American Journal of Clinical Pathology·Christopher D M Fletcher, Jonathan A Fletcher
May 20, 2003·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Mojgan Devouassoux-ShisheboranMohamed Benahmed
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group

❮ Previous
Next ❯

Citations

Jun 2, 2007·Journal of Molecular Histology·Mihail E HinescuLaurentziu M Popescu
Jul 8, 2005·Expert Review of Proteomics·Till BraunschweigStephen M Hewitt
Nov 6, 2007·Expert Opinion on Emerging Drugs·Florian Eckel, Roland M Schmid
Sep 23, 2006·Scandinavian Journal of Gastroenterology·Xiaomin SunHesheng Luo
May 19, 2006·Journal of Hepato-biliary-pancreatic Surgery·Shogo TanakaShoji Kubo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.